In this article, we will discuss the 10 stocks recently downgraded by analysts. If you want to see more such stocks on the list, you can directly visit Analysts on Wall Street Lower Ratings for These 5 Stocks.
On March 12, stock markets experienced a surge as traders engaged in hedging strategies in response to potential movements following the release of Consumer Price Index (CPI) data. The Japanese yen, after a six-day streak, exhibited weakness against the US dollar. Notably, UK stocks demonstrated strong performance following the release of favorable jobs data, while Treasury yields remained stable. European stocks and US equity futures displayed gains in anticipation of the awaited US inflation figures, which are crucial in determining the Federal Reserve’s stance on monetary policy adjustments. The Stoxx Europe 600 index saw a rise of 0.6%, primarily driven by increases in energy, basic resources, and technology sectors. Meanwhile, UK stocks stood out with notable strength, reflecting a cooling trend in the job market as indicated by recent data. Futures for the S&P 500 and Nasdaq 100 also showed positive movements, increasing by 0.4% and 0.7%, respectively. Concurrently, US Treasury yields maintained stability, while the performance of the dollar remained relatively unchanged. The underlying inflation in the United States has exceeded expectations for the second consecutive month in February. This increase was primarily driven by notable price hikes in categories such as used cars, air travel, and clothing, which have contributed to reinforcing the Federal Reserve’s cautious stance on reducing interest rates. Specifically, the core consumer price index, which excludes volatile food and energy prices, saw a significant uptick of 0.4% compared to January, as revealed by government data released on Tuesday. On a year-over-year basis, this index surged by 3.8%. This persistent rise in core inflation suggests ongoing pressures in certain sectors of the economy, prompting the Fed to maintain a vigilant approach in its monetary policy decisions. The central bank’s reluctance to swiftly cut interest rates reflects its concern about potential overheating and the need to balance economic growth with inflationary risks.
Oil prices experienced fluctuations amidst indications of persistent inflation in the United States, causing turbulence across broader markets while investors remained steadfast in their expectations of a potential interest rate cut by the Federal Reserve in the current year. The West Texas Intermediate (WTI) benchmark surpassed $78 per barrel, buoyed by a rebound in equities despite an inflation figure surpassing expectations. Concurrently, Brent futures surged to exceed $82 per barrel. Alongside the economic indicators from the US, OPEC’s monthly report revealed that recent efforts to curtail oil supply were hindered as Iraq surpassed its production quota for the second consecutive month. This development added further complexity to the dynamics influencing global oil prices. Despite an overall upward trend in oil prices for the year, they have largely remained confined within a narrow trading range. This persistence of prices within a constrained spectrum indicates ongoing market indecision and potential volatility ahead.
10. Bilibili Inc. (NASDAQ:BILI)
Price Reaction after the Downgrade: +1.48 (+13.30%)
On March 11, Bilibili Inc. (NASDAQ:BILI), a prominent player in the online entertainment industry, saw a significant surge in its market price, climbing by 13.30% by the closing bell, reaching $12.61. This uptick followed a downgrade by Citi analyst Brian Gong, who shifted the stock’s rating from Buy to Neutral, with a revised price target of $12.50, down from $18. Gong’s decision stemmed from a recalibration of revenue estimates for 2024 and 2025, reflecting a subdued outlook for the company’s gaming and other segments, as evidenced by its Q4 report. According to Gong, Bilibili Inc. (NASDAQ:BILI) gaming and other businesses are facing headwinds that have prompted the revision of revenue projections. While the company has shown decent momentum in its live streaming segment, Gong believes that this alone may not be sufficient to drive investor enthusiasm, especially given Bilibili’s modest valuation compounded by regulatory uncertainties. Moreover, the gaming division, which historically served as a key growth driver, currently lacks clear catalysts for growth. The downgrade by Citi, despite the subsequent surge in market price, underscores concerns about Bilibili Inc. (NASDAQ:BILI) growth trajectory and the challenges it faces in navigating the regulatory landscape while sustaining momentum across its various business verticals. As investors weigh the implications of Gong’s revised outlook, Bilibili Inc. (NASDAQ:BILI) may need to demonstrate tangible strategies to address these concerns and reignite investor confidence in its long-term prospects.
Artisan Developing World Fund made the following comment about Bilibili Inc. (NASDAQ:BILI) in its second quarter 2023 investor letter:
“Bottom contributors to performance for the quarter included Chinese video streaming platform Bilibili Inc. (NASDAQ:BILI). Bilibili fell after reported gaming revenue decay in legacy titles and an underwhelming advertising recovery, though cost-cutting measures and balance sheet optimization have been visible.”
09. Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX)
Price Reaction after the Downgrade: +0.4400 (+13.0952%)
On March 11, Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX), a notable player in the pharmaceutical industry, witnessed a remarkable 13.0952% surge in its market price, reaching $3.80 after Leerink, a renowned financial analyst firm, downgraded its rating on the stock from Outperform to Market Perform. Alongside this rating adjustment, Leerink also slashed the price target for Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) from $27 to $4. The catalyst for this downgrade was the disappointing top-line results from the PHOENIX study, which failed to meet expectations. According to Leerink, the outcome of the PHOENIX study was “very disappointing,” prompting concerns among investors regarding the future prospects of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX). There are apprehensions that Amylyx may withdraw the drug from the market due to lackluster results, while also continuing to allocate resources towards other development projects that have yet to demonstrate a solid proof-of-concept.
During the conference call following the study results, Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) management reiterated its commitment to ongoing programs in Wolfram Syndrome and Progressive Supranuclear Palsy. Despite having a substantial cash reserve of $370 million, Leerink believes that, given the current circumstances, it is prudent to adopt a cautious approach and step to the sidelines. Leerink’s downgrade underscores the challenges and uncertainties facing Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) as it navigates through a pivotal phase in its development pipeline. As investors digest the implications of the downgrade and reassess their positions, Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) may need to articulate a clear strategy to address the concerns raised by Leerink and regain investor confidence in its long-term viability and growth prospects.
08. Bristol-Myers Squibb Company (NYSE:BMY)
Price Reaction after the Downgrade: +0.57 (+1.06%)
On March 11, Bristol-Myers Squibb Company (NYSE:BMY), a prominent player in the pharmaceutical industry, experienced a modest 1.06% increase in its market price, closing at $54.39 after Societe Generale, a respected financial institution, downgraded its rating on the stock from Buy to Hold. Alongside this downgrade, Societe Generale also revised its price target for Bristol-Myers Squibb Company (NYSE:BMY) to $51. The rationale behind this downgrade stems from the perceived challenges faced by Bristol Myers in its product cycle and the formidable task of addressing its top-line issues. According to the analyst at Societe Generale, the pharmaceutical product cycle is inherently lengthy, and given the significant scale of the top-line challenge confronting Bristol-Myers Squibb Company (NYSE:BMY), investors must exercise extreme patience to potentially reap the benefits of any future re-rating. This downgrade sheds light on the hurdles ahead for Bristol-Myers Squibb Company (NYSE:BMY) as it navigates through the intricacies of the pharmaceutical landscape. With the need for patience underscored by Societe Generale, investors may adopt a more cautious stance towards Bristol Myers, awaiting tangible signs of progress and growth in the company’s performance and market positioning.
Aristotle Atlantic Core Equity Strategy stated the following regarding Bristol-Myers Squibb Company (NYSE:BMY) in its fourth quarter 2023 investor letter:
“We sold our position in Bristol-Myers Squibb Company (NYSE:BMY), following the third quarter earnings report where the company reduced the medium-term guidance on the new product portfolio and lowered its 2025 target. Given the large amount of revenue associated with drugs going off-patent, the new product portfolio was key to the company’s ability to change investor perception. Certain launches are not performing as expected, and others are taking longer to scale. Additionally, Bristol-Myers reduced medium-term operating margin guidance to invest in its commercial drugs and the research and development (R&D) pipeline. We do not believe that the company exhibited the level of defensiveness in the strategy we expected given the low valuation.”
07. PDD Holdings Inc. (NASDAQ:PDD)
Price Reaction after the Downgrade: +1.55 (+1.40%)
On March 11, PDD Holdings Inc. (NASDAQ:PDD), a player in the e-commerce industry, experienced a notable shift in market dynamics following Goldman Sachs’ decision to downgrade its rating from Buy to Neutral. This downgrade came with a revised price target of $136, significantly lower than the previous target of $196. The reasoning behind this decision stems from Goldman Sachs’ re-evaluation of the risk-reward scenario in light of recent developments. Goldman Sachs pointed out two key factors influencing their decision. Firstly, there has been a significant evolution in the policy landscape pertaining to cross-border businesses, notably highlighted by the passage of the H.R.7521 bill by the House Energy and Commerce Committee in the United States. This bill specifically targets foreign apps, which could potentially impact companies like PDD Holdings Inc. (NASDAQ:PDD) that operate across borders. Secondly, the firm highlighted the strategic shifts among domestic e-commerce peers, particularly evident in recent earnings reports. Companies like Alibaba (BABA) have articulated a renewed focus on growth for 2024, with a specific emphasis on reigniting gross merchandise volume (GMV) growth. This strategic realignment among competitors suggests a potentially heightened competitive landscape for PDD. Following this downgrade, PDD Holdings Inc. (NASDAQ:PDD) market price experienced a modest increase of 1.40% by the closing bell on March 11, settling at $111.89. This shift in market sentiment reflects investors’ reaction to the revised outlook provided by Goldman Sachs and the broader implications of the identified market dynamics on PDD Holdings Inc. (NASDAQ:PDD) future prospects.
Baron Emerging Markets Fund stated the following regarding PDD Holdings Inc. (NASDAQ:PDD) in its fourth quarter 2023 investor letter:
“We added to our digitization theme by building a position in PDD Holdings Inc. (NASDAQ:PDD), a leading Chinese e-commerce platform. Founded in 2015, the company has emerged as China’s second largest e-commerce player, capturing approximately 20% market share. In our view, PDD’s competitive moat lies in its team purchase model that facilitates bulk buying through direct partnerships with manufacturers, thereby eliminating intermediaries (e.g., distributors and middlemen) and lowering costs. Key factors driving the company’s meteoric growth include rising consumer demand for affordable products in China amid an economic slowdown, small-scale merchants seeking alternatives to Alibaba, and superior management execution. PDD’s revenue growth outpaces gross merchandize value growth owing to rising take rates as merchants aggressively compete for consumer traffic on the platform. In our view, PDD should continue to gain market share given its dominance in the value-for-money segment, growing affordable branded product offerings, and high operational efficiency. We believe the company’s growth will be further supported by the recent launch of its international e-commerce platform, Temu, which has become one of the fastest growing apps globally. Leveraging China’s excess manufacturing capacity, Temu has strong negotiating power with domestic suppliers and attracts global consumers with competitively priced products. Temu’s recent initiatives to improve unit economics, coupled with achieving variable breakeven in the sizable U.S. market, showcase management’s skill and commitment to sustained growth. We expect PDD to at least double its earnings and free cash flow in the next three years, with the potential for continued compounding thereafter.”
06. American Electric Power Company, Inc. (NASDAQ:AEP)
Price Reaction after the Downgrade: -0.11 (-0.13%)
On March 11, the stock of American Electric Power Company, Inc. (NASDAQ:AEP), a prominent player in the energy industry, experienced a noteworthy event as UBS Group revised their rating downward from Neutral to Sell. Alongside this change, their price target was adjusted from $86.00 to $83.00. Consequently, there was a slight decline of 0.13% in the market price of American Electric Power Company, Inc. (NASDAQ:AEP) by the time the closing bell rang on March 11, with the current value resting at $83.73. This downgrade and subsequent adjustment in price target reflect UBS Group’s revised outlook on American Electric Power Company, Inc. (NASDAQ:AEP) performance, potentially indicating shifts in market sentiment and investor confidence towards the company’s future prospects.
Click to continue reading and see Analysts on Wall Street Lower Ratings for These 5 Stocks.
Suggested articles:
- Wall Street Picked These 13 AI Stocks for 2024
- 12 Most Undervalued Biotech Stocks To Buy According To Hedge Funds
- 13 Best Stocks To Buy and Hold Forever
Disclosure. None. Analysts on Wall Street Lower Ratings for These 10 Stocks is originally published on Insider Monkey.
